Literature DB >> 373434

Patient factors contributing to the emergence of gentamicin-resistant Serratia marcescens.

V L Yu, C A Oakes, K J Axnick, T C Merigan.   

Abstract

One hundred forty nosocomial Serratia marcescens infections (including 76 cases of bacteremia) were identified by prospective surveillance from 1975 through 1977 and retrospective chart review from 1968 through 1974. Thirty-four cases (24 per cent) involved gentamicin-resistant strains. All gentamicin-resistant strains appeared after 1974. Ninety per cent of the patients had undergone surgery, and 88 per cent had received prior antimicrobial therapy. The emergence of gentamicin-resistant S. marcescens paralleled the increase in usage of gentamicin. Prior use of gentamicin for more than two days in an individual patient was a significant risk factor (P = 0.0002) for being infected with a Serratia that was gentamicin-resistant. Other factors which separated gentamicin-resistant Serratia infections from gentamicin-sensitive Serratia infections were (1) urinary site of infection (P = 0.0005), (2) urinary catheter (P = 0.002), (3) endotracheal tube or tracheotomy (P = 0.03) and (4) increasing duration of hospitalization (P less than 0.05). Thirty-three of 34 (97 per cent) patients with gentamicin-resistant strains had urinary catheters. Specific measures to control infection were effective in decreasing the incidence of infections caused by gentamicin-resistant Serratia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373434     DOI: 10.1016/0002-9343(79)91074-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Sequential epidemic outbreaks of septicaemias by Serratia and Klebsiella species on a medical intensive care unit.

Authors:  J L Cortés; E Domínguez-de Villota; A Algora-Weber; C Chamorro; M C Torrecilla; J M Mosquera
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Serratia sp. bacteremia in Canberra, Australia: a population-based study over 10 years.

Authors:  H J Engel; P J Collignon; P T Whiting; K J Kennedy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-05       Impact factor: 3.267

3.  A regional survey of the resistance to beta-lactam antibiotics in clinical isolates of (facultative) aerobic micro-organisms.

Authors:  E E Stobberingh; J M Philips; A W Houben; C P van Boven
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Bacterial resistance: exploring the facts and myths.

Authors:  B R Meyers
Journal:  Bull N Y Acad Med       Date:  1987-04

5.  Antibiotic resistance in Serratia marcescens.

Authors:  J D Sleigh
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

6.  Outer membrane and porin characteristics of Serratia marcescens grown in vitro and in rat intraperitoneal diffusion chambers.

Authors:  F Malouin; G D Campbell; M Halpenny; G W Becker; T R Parr
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

7.  Case-control analysis of endemic Serratia marcescens bacteremia in a neonatal intensive care unit.

Authors:  Matthew J Bizzarro; Louise-Marie Dembry; Robert S Baltimore; Patrick G Gallagher
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11-06       Impact factor: 5.747

8.  Outbreak of nosocomial urinary tract infections caused by Serratia marcescens.

Authors:  T Okuda; N Endo; Y Osada; H Zen-Yoji
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

9.  Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.

Authors:  S M Markowitz; D J Sibilla
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

10.  Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland.

Authors:  Danesh Moradigaravand; Christine J Boinett; Veronique Martin; Sharon J Peacock; Julian Parkhill
Journal:  Genome Res       Date:  2016-07-18       Impact factor: 9.043

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.